Statin Treatment Is Associated with Reduction in Serum Levels of Receptor Activator of NF-κB Ligand and Neutrophil Activation in Patients with Severe Carotid Stenosis
Table 4
Serum cardiovascular risk markers.
Characteristics
Statin ()
No statin ()
-value
CRP*, mg/L
2.4 (0.96–4.03)
4.1 (1.43–8.41)
0.1782
OPN, ng/mL
17.5 (12.8–23.8)
29.4 (23.2–34.6)
0.0131
RANKL, pg/mL
1022 (247–1669)
1839 (1551–2803)
0.0050
OPG, pg/mL
167.8 (62.3–318.1)
62.3 (62.3–432.0)
0.0182
RANKL/OPG ratio
5.8 (1.5–17.1)
27.2 (15.5–43.3)
0.0004
MPO, ng/mL
265.2 (101.8–531.6)
466.0 (313.7–841.9)
0.1014
Neutrophil elastase, ng/mL
211.1 (109.1–318.6)
325.3 (143.1–450.2)
0.1489
MMP†-8, ng/mL
16.5 (5.8–23.7)
12.7 (4.0–24.7)
0.7579
MMP-9, ng/mL
231.5 (134.9–431.6)
479.0 (352.8–812.5)
0.0461
Pro-MMP-9 activity, ng/mL
6.8 (3.1–14.4)
13.1 (11.9–18.2)
0.0310
MMP9/TIMP-1, ng/mL
10.6 (6.4–18.4)
14.4 (2.8–23.0)
0.8839
TIMP‡-1, ng/mL
191.3 (120.0–216.7)
211.0 (147.6–264.6)
0.3389
TIMP-2, ng/mL
101.4 (65.4–124.5)
97.0 (73.0–112.2)
0.8078
TIMP-3, ng/mL
8.1 (4.7–14.9)
12.5 (6.2–13.8)
0.5824
TIMP-4, ng/mL
5.4 (3.6–6.6)
4.2 (4.0–6.1)
0.7579
Data are expressed as median (interquartile range (IQR)).
*CRP: C-reactive protein. †MMP: matrix metalloproteinase. ‡TIMP: tissue inhibitor of metalloproteinase.
